Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Valérie Grégoire"'
Autor:
Marie Fernandes, Brynna Hoggard, Philippe Jamme, Sonia Paget, Marie‐José Truong, Valérie Grégoire, Audrey Vinchent, Clotilde Descarpentries, Angela Morabito, Justas Stanislovas, Enoir Farage, Jean‐Pascal Meneboo, Shéhérazade Sebda, Katia Bouchekioua‐Bouzaghou, Marie Nollet, Sarah Humez, Timothy Perera, Paul Fromme, Luca Grumolato, Martin Figeac, Marie‐Christine Copin, David Tulasne, Alexis B. Cortot, Stéphanie Kermorgant, Zoulika Kherrouche
Publikováno v:
Molecular Oncology, Vol 17, Iss 11, Pp 2257-2274 (2023)
Exon skipping mutations of the MET receptor tyrosine kinase (METex14), increasingly reported in cancers, occur in 3–4% of non–small‐cell lung cancer (NSCLC). Only 50% of patients have a beneficial response to treatment with MET‐tyrosine kinas
Externí odkaz:
https://doaj.org/article/272f451e35f5414da2913aa27cf75f12
Autor:
Marie Fernandes, Brynna Hoggard, Philippe Jamme, Sonia Paget, Marie‐José Truong, Valérie Grégoire, Audrey Vinchent, Clotilde Descarpentries, Angela Morabito, Justas Stanislovas, Enoir Farage, Jean‐Pascal Meneboo, Shéhérazade Sebda, Katia Bouchekioua‐Bouzaghou, Marie Nollet, Sarah Humez, Timothy Perera, Paul Fromme, Luca Grumolato, Martin Figeac, Marie‐Christine Copin, David Tulasne, Alexis B. Cortot, Stéphanie Kermorgant, Zoulika Kherrouche
Publikováno v:
Molecular Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f2ac32aff2b1a266e3f7d78cf49862c
https://doi.org/10.1002/1878-0261.13397
https://doi.org/10.1002/1878-0261.13397
Autor:
Valérie Grégoire, Philippe Jamme, Mark M. Awad, C. Descarpentries, Marie-Christine Copin, Enrico Patrucco, Roberto Chiarle, Eric Wasielewski, Alexis B. Cortot, Simon Baldacci
Publikováno v:
Lung Cancer. 146:366-369
Objective Immune checkpoint inhibitors (ICI) have become a major treatment in advanced non small cell lung cancer (NSCLC). However, some patients do not benefit from ICI, especially those harboring an ALK rearrangement. Here, we report a case of prol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d45c6999c5dfe2fd4f479ed826dc1502
https://doi.org/10.1016/j.lungcan.2020.05.008
https://doi.org/10.1016/j.lungcan.2020.05.008
Autor:
Anthony Turpin, Clotilde Descarpentries, Valérie Grégoire, Olivier Farchi, Alexis B Cortot, Philippe Jamme
Publikováno v:
The oncologist.
Cholangiocarcinoma is the second most common liver cancer after hepatocellular carcinoma. In case of metastatic or unresectable disease, the recommended first-line treatment is gemcitabine-based doublet, most commonly gemcitabine and cisplatin. There
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a349e5f4e6f3d9c4d1d4fd34b8bd2e6e
https://pubmed.ncbi.nlm.nih.gov/36434677
https://pubmed.ncbi.nlm.nih.gov/36434677
Autor:
Philippe Jamme, C. Descarpentries, Marie-Christine Copin, Fabienne Escande, Valérie Grégoire, Shéhérazade Sebda, Alexis B. Cortot, Martin Figeac, Frédéric Leprêtre, Simon Baldacci, David Tulasne, Zoulika Kherrouche
Publikováno v:
Journal of Thoracic Oncology. 13:1873-1883
Introduction Genomic alterations affecting splice sites of MNNG HOS transforming gene (MET) exon 14 were recently identified in NSCLC patients. Objective responses to MET tyrosine kinase inhibitors have been reported in these patients. Thus, detectio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62660cd9dd9b0e2d88a8f5338ee28649
https://doi.org/10.1016/j.jtho.2018.08.2023
https://doi.org/10.1016/j.jtho.2018.08.2023
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Valérie Grégoire, Marie-Christine Copin, David Tulasne, Alexis B. Cortot, Camille Lapere, Vincent Cockenpot
Publikováno v:
American Journal of Surgical Pathology. 41:414-422
The involvement of the HGF/MET pathway in acquisition of an invasive phenotype in non-small cell lung carcinomas (NSCLCs) suggests that MET inhibitors might prove effective against these cancers, but clinical trials have yielded conflicting results.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cea53fcca31473051fa654497bd76e2f
https://doi.org/10.1097/pas.0000000000000810
https://doi.org/10.1097/pas.0000000000000810
Autor:
Fabienne Escande, Marie Fernandes, Zoulika Kherrouche, Angela Morabito, Matthieu Jamme, David Tulasne, Alexis B. Cortot, C. Descarpentries, Marie-Christine Copin, Philippe Jamme, Simon Baldacci, Valérie Grégoire
Publikováno v:
Journal of Thoracic Oncology
Journal of Thoracic Oncology, 2020, 15, pp.741-751. ⟨10.1016/j.jtho.2020.01.027⟩
Journal of Thoracic Oncology, Lippincott, Williams & Wilkins, 2020, 15, pp.741-751. ⟨10.1016/j.jtho.2020.01.027⟩
Journal of Thoracic Oncology, 2020, 15, pp.741-751. ⟨10.1016/j.jtho.2020.01.027⟩
Journal of Thoracic Oncology, Lippincott, Williams & Wilkins, 2020, 15, pp.741-751. ⟨10.1016/j.jtho.2020.01.027⟩
Hepatocyte growth factor receptor (MET) tyrosine kinase inhibitors (MET TKIs) have been found to have efficacy against advanced NSCLC with mutations causing MET exon 14 skipping (METex14 mutations), but primary resistance seems frequent, as response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c83effdf8573f4b4827c56d30da0f14
https://pubmed.ncbi.nlm.nih.gov/32340672
https://pubmed.ncbi.nlm.nih.gov/32340672
Autor:
Marie Christine Copin, Philippe Jamme, Radj Gervais, Valérie Grégoire, Nathalie Rabbe, Nicolas Richard, Simon Baldacci, Alexis B. Cortot, Fabienne Escande, Maeva Kyheng, Marie Wislez, Eric Dansin, Zoulika Kherrouche, C. Descarpentries
Publikováno v:
Clinical Lung Cancer
Clinical Lung Cancer, Elsevier, 2019, 20 (4), pp.297-304.e1. ⟨10.1016/j.cllc.2019.02.013⟩
Clinical Lung Cancer, 2019, 20 (4), pp.297-304.e1. ⟨10.1016/j.cllc.2019.02.013⟩
Clinical Lung Cancer, Elsevier, 2019, 20 (4), pp.297-304.e1. ⟨10.1016/j.cllc.2019.02.013⟩
Clinical Lung Cancer, 2019, 20 (4), pp.297-304.e1. ⟨10.1016/j.cllc.2019.02.013⟩
Background Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have shown efficacy in the treatment of ALK-rearranged non–small-cell lung cancer (NSCLC), but the disease eventually progresses in all patients. In many cases, resistanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8131ac1211fcec2c008eebd3d7e8788
https://hal-normandie-univ.archives-ouvertes.fr/hal-02267645
https://hal-normandie-univ.archives-ouvertes.fr/hal-02267645
Autor:
Fabienne Escande, Dan Petre Tica, Sébastien Aubert, Marie Jeanneau, Valérie Grégoire, Xavier Leroy, Claude Desplechain
Publikováno v:
Pathology - Research and Practice. 212:1064-1066
We report an exceptional case of renal cell carcinoma (RCC) associated with ALK translocation in an adult. The tumor was located in the left kidney and measured 4cm. The tumor was composed of sheets of large eosinophilic cells with frequently intracy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f69bfee74dc463f51b9f9f699c39690c
https://doi.org/10.1016/j.prp.2016.07.015
https://doi.org/10.1016/j.prp.2016.07.015